Finalo

Quick links to important sections

Finalo

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Finalo

Quick Facts: Finasteride (Finalo)

Property Description
Active ingredient Finasteride
Form Oral tablet
Pharmacological class 5-Alpha Reductase Inhibitor
Common use Modulating androgen-related conditions
Origin Synthetic 4-azasteroid compound

What Type of Medicine is Finalo? (Finasteride's Identity and Class)

Finalo is a pharmaceutical product whose active therapeutic compound is Finasteride, an orally administered, single-ingredient medicine typically reserved for use in adult males. The compound itself is a synthetic 4-azasteroid compound and is classified within the established pharmacological class of 5-Alpha Reductase Inhibitors (5-ARI). This class is characterized by its ability to modulate steroid hormone metabolism. The medicine is supplied as a solid oral tablet, intended for systemic administration, which is a key distinction from non-systemic treatments. Its prescription-only status confirms that its use requires professional guidance.

What is the General Purpose of a 5-Alpha Reductase Inhibitor?

The primary, high-level purpose of Finasteride is to reduce the physiological influence of the powerful male hormone metabolite, Dihydrotestosterone (DHT), within the body. This is achieved through its fundamental action as a specific inhibitor of the Type II 5-alpha reductase isoenzyme, the enzyme responsible for converting Testosterone into the more potent DHT. This drug classification works by blocking the core enzyme that produces the Dihydrotestosterone hormone. By blocking this crucial enzymatic step, the medicine effectively lowers the concentration of DHT in serum and targeted tissues. The clinical relevance of this action is its ability to serve as an antiandrogen, providing a targeted therapeutic effect by counteracting the consequences of DHT-driven tissue stimulation.

What side effects are possible with Finalo?

Possible Side Effects and Safety Information

The safety profile of Finalo (Finasteride) describes documented adverse reactions primarily concerning the reproductive system, along with specific population constraints and post-marketing observations, based strictly on regulatory labeling.

Adverse Reaction Classification

Adverse reactions are classified by frequency as observed in clinical data and post-marketing surveillance. The most frequently documented effects are generally concentrated in the sexual domain.

Regulatory Frequency Example Adverse Reactions (System-Organ Class)
Common (ge 1/100 to <1/10) Decreased libido, erectile dysfunction, ejaculation disorder, breast enlargement (gynecomastia), breast tenderness (Reproductive System and Breast Disorders)
Uncommon (ge 1/1,000 to <1/100) Skin rash (Skin and Subcutaneous Tissue Disorders), testicular pain (Reproductive System)
Not Known (Post-marketing) Depression, anxiety, suicidal ideation (Psychiatric Disorders), persistent sexual dysfunction after discontinuation, male breast cancer (Oncologic), hypersensitivity reactions (Immune System Disorders)

Safety Considerations and Restrictions

Most common sexual adverse reactions often appear early in the course of therapy and, for many, may resolve with continued use. However, regulatory documents note that certain sexual side effects and psychiatric symptoms have been reported to persist after discontinuation of treatment. Serious but rare reactions documented include male breast cancer and an increased risk of high-grade prostate cancer (observed primarily with the 5 mg dose).

Finasteride is contraindicated in women who are or may become pregnant due to the potential risk of causing external genitalia abnormalities in a male fetus. It is not indicated for use in children. Official regulatory notes require that serum Prostate-Specific Antigen (PSA) levels be doubled when evaluating screening results, as the medicine significantly lowers the true PSA reading. These constraints and classifications define the boundaries of the drug’s documented safety profile.

Overdose and Emergency Response

The official regulatory documents provide specific information regarding the manifestation and management of Finasteride overexposure. Acute human overexposure to the drug has been formally assessed in clinical studies. Patients who received single doses up to 400 mg and multiple doses up to 80 mg/day for a period of three months did not exhibit documented adverse effects or specific clinical symptoms. This official finding indicates a high tolerance for doses significantly exceeding the standard therapeutic range.

Despite the documented lack of specific symptoms in high-dose human studies, the official guidance requires individuals to seek immediate medical attention or contact a regional poison control centre in the event of any suspected overexposure. This regulatory instruction is critical because no specific treatment or antidote is recommended for finasteride overdose. The management approach is therefore constrained to be entirely symptomatic and supportive. This means clinical oversight and observation are necessary to manage any potential non-specific or emergent symptoms that may arise. Population-specific overdose considerations for elderly, pediatric, or renally impaired individuals are not distinctly documented in the official overdose sections.

Therapeutic Uses of Finalo

What Finalo Treats

Finalo is primarily indicated for the treatment of male pattern hair loss, also known as androgenetic alopecia. This condition is characterized by a gradual thinning of the hair on the scalp, often resulting in a receding hairline or thinning at the crown.

Main Uses

The medication is used to manage and treat hair loss specifically in men. It works by addressing the underlying hormonal factors that contribute to the shrinking of hair follicles. By inhibiting the conversion of testosterone into dihydrotestosterone (DHT), the medication helps to maintain existing hair and can promote regrowth in some areas of the scalp.

Benefits and Expected Outcomes

The primary goal of treatment with Finalo is to stabilize hair loss and improve hair density over time. Users may observe several clinical benefits throughout the course of treatment:

  • Reduction in Hair Shedding: Many individuals notice a decrease in the amount of hair lost daily after consistent use.
  • Increased Hair Count: Treatment can lead to an increase in the number of visible hairs in thinning areas.
  • Improved Scalp Coverage: As hair follicles are preserved and growth is stimulated, the overall appearance of hair thickness and scalp coverage may improve.
  • Maintenance of Existing Hair: For many, the most significant benefit is the prevention of further progression of male pattern baldness.

It is important to note that the effects of this treatment are typically observed over a period of several months, as the hair growth cycle is a slow process. Continuous use is generally required to maintain the benefits achieved during the treatment period.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Finalo?

Finasteride (Finalo) is restricted to a highly specific patient population as defined by governmental regulatory documents (e.g., FDA and EMA). The drug is primarily indicated for use only in adult males who are being treated for approved conditions.


Absolute Contraindications

Finalo is formally contraindicated and must not be used in the following populations:

  • Females: The drug is not indicated for use in women for any purpose.
  • Pregnancy: Women who are or may become pregnant are absolutely prohibited from using Finalo or handling crushed/broken tablets due to the risk to a male fetus.
  • Pediatric Patients: Use is contraindicated in children and adolescents, as safety and efficacy have not been established in patients under 18 years of age.
  • Hypersensitivity: Individuals with a known hypersensitivity or allergic reaction to finasteride or any component of the formulation.

Condition-Based Eligibility Rules

Population Group Regulatory Status
Renal Impairment No dosage adjustment is necessary in patients with chronic kidney impairment.
Hepatic Impairment Caution is advised in patients with liver function abnormalities, as the medicine is metabolized extensively in the liver.
Older Adults (Geriatric) No dosage adjustment is necessary in the elderly population.

What should I know about interactions with other medicines?

Finasteride (Finalo) is an inhibitor of the enzyme 5-alpha reductase, and its official regulatory labeling indicates that no drug interactions of clinical significance have been identified in formal studies. This suggests that the medicine has a low potential to cause clinically significant interactions when taken with most other commonly used medications.

However, healthcare providers should be aware of the following official information regarding how the drug is processed in the body and tested combinations:

  • Enzyme System Interaction: Finasteride is primarily metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme subfamily in the liver. Despite this, the drug does not appear to affect or inhibit the overall CYP450-linked drug-metabolizing enzyme system. This lack of effect is the primary basis for the minimal interaction profile.
  • Tested Compounds: Clinical studies have specifically tested finasteride in combination with several compounds, finding no clinically meaningful interactions. The tested substances include antipyrine, digoxin, propranolol, theophylline, and warfarin.

Patients should always inform their healthcare professional of all current medications, supplements, and herbal products, as this provides the most complete information for safe treatment planning.

Mechanism of Action

How Finalo Works

The mechanism of Finalo (Finasteride) is defined by its highly specific action on steroid hormone metabolism, resulting in specific modulation of tissue growth and cellular regulation.


Selective Inhibition of DHT Synthesis

This mechanism targets the 5-alpha reductase Type II enzyme, acting as a competitive inhibitor to block the conversion of Testosterone into the structurally more active androgen Dihydrotestosterone (DHT). This molecular action results in a profound and sustained decrease in both circulating and localized DHT concentrations, primarily in androgen-sensitive tissues such as the prostate and hair follicles.


Alteration of Cellular Homeostasis

The resulting reduction in DHT stimulation initiates a crucial mechanistic cascade within these target tissues. By removing the growth-promoting signal of DHT, the drug initiates the induction of apoptosis (programmed cell death) and reduces cellular proliferation. This slow but fundamental change in cellular homeostasis is what drives the physiological reduction in tissue volume and the reversal of hair follicle miniaturization.


This mechanism modulates the core hormonal pathway governing androgen-dependent cell proliferation and volume.

Dosage and Administration Information

How to use Finalo

Finalo is administered as an oral tablet on a once-daily schedule. The specific dose corresponds to the condition being managed: 5 mg daily for Benign Prostatic Hyperplasia (BPH) and 1 mg daily for Androgenetic Alopecia.

The usage pattern involves continuous, long-term administration. A period of six months or more is typically required before the therapeutic pattern can be accurately assessed.

The tablets may be taken with or without food. For proper intake, the tablets must be swallowed whole and must not be crushed or broken.

Administration is limited to adult males; the medicine is not indicated for use in children or adolescents. In the event of a missed dose, the procedure is to not take an extra tablet to compensate, but to continue the treatment with the next scheduled dose. The administration protocol remains standardized for older adult males and for those with renal impairment, as no dosage adjustment is typically required for these groups.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Finalo

The information presented here summarizes the findings and structure of the official research, primarily consisting of randomized controlled trials (RCTs) and meta-analyses, that has examined Finasteride, the active ingredient in Finalo. This overview is purely descriptive and does not offer clinical advice or personal recommendations.


Evidence for Use in Benign Prostatic Hyperplasia (BPH) and LUTS

Finalo was studied for managing symptomatic Benign Prostatic Hyperplasia (BPH) and associated Lower Urinary Tract Symptoms (LUTS) in adult men. Research examined the compound through large-scale, placebo-controlled RCTs that often tracked participants over several years. These studies used standardized scores to monitor how symptoms change over time, alongside objective measurements like prostate volume and maximum urinary flow rate ( Q max).

The findings describe patterns observed in the studies where treatment was associated with measured changes in prostate volume and shifts in standardized symptom scores. Long-term studies, in particular, reported how symptoms evolved in the observed populations, indicating that the incidence of specific BPH-related complications (e.g., acute urinary retention) showed a difference in pattern between the treated groups and the control groups.


Evidence for Use in Androgenetic Alopecia (AGA)

The research exploring Finasteride for Androgenetic Alopecia (AGA), or male pattern hair loss, also relies on double-blind, placebo-controlled RCTs. These studies were evaluated in men typically between the ages of 18 and 41 with mild-to-moderate hair loss on the vertex (crown) and mid-scalp areas. Researchers examined outcomes related to hair count and changes in the appearance of hair coverage using independent reviews of standardized clinical photographs.

Studies report how symptoms evolved in the observed populations, showing that hair count measurements were observed in some studies to shift in the treated groups over periods of one to two years, while participants receiving placebo generally continued to experience decreases in hair count. Photographic assessments contribute to understanding symptom patterns, indicating that coverage of the thinning areas can appear stabilized or changed in a measurable way compared to the baseline condition.


What is Still Uncertain in the Research Landscape

While a significant amount of research was conducted for Finalo, there are areas where certainty remains low or where data is scarce:

  • Follow-up durations were limited in some initial trials, meaning the full, multi-decade effects of use may not be completely characterized.
  • The research does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes.
  • Research evidence is not yet comprehensive for many general long-term outcomes outside of the specific measures examined in the core clinical trials (e.g., impact on overall quality of life across all domains).

Frequently Asked Questions (FAQ)

Common questions about Finalo (FAQ)


Q: Is Finalo the same as other medicines with similar names?

A: Finalo contains the active ingredient Finasteride, which is a unique chemical compound. Other medicines may treat similar conditions but contain different active ingredients. Official product information is the source for verifying a medicine's specific ingredients.


Q: How long does it usually take to notice effects from Finalo?

A: Finalo is described in official documents as a long-term treatment. Official documents note that a period of at least six months is typically required before therapeutic patterns can be accurately assessed, which is when changes may start to be observed.


Q: If I stop taking Finalo, do the effects go away?

A: Regulatory documents note that the observed benefits from the drug are generally lost within 12 months after stopping treatment, as the drug's effect is only present while it is being taken.


Q: Are there any serious or rare side effects I should know about for Finalo?

A: Regulatory documents describe serious but rare events that have been reported. These include an increased risk of high-grade prostate cancer (with the 5 mg dose) and rare reports of male breast cancer. Additionally, psychiatric symptoms such as depression and suicidal ideation have been noted in post-marketing reports.


Q: Does Finalo affect the results of certain medical tests?

A: Yes, Finalo significantly affects the measurement of Prostate-Specific Antigen (PSA) levels. Regulatory guidelines specify that a correction factor is used by healthcare professionals when evaluating PSA test results for screening purposes.


Q: Why is Finalo prescribed in different doses for different conditions?

A: Official drug labels state that the approved dosage is specific to the condition being managed. The two approved conditions—Benign Prostatic Hyperplasia (BPH) and Androgenetic Alopecia (AGA)—have different established doses based on clinical research.


Q: Are there different brand names for the same active ingredient as Finalo?

A: Finasteride is the active ingredient in Finalo. This compound is also sold under other brand names.


Q: Is it normal to feel nauseous when starting Finalo?

A: Nausea is generally not listed among the commonly reported or rare adverse reactions documented in the official safety information for Finalo.


Q: What are the restrictions on donating blood while taking Finalo?

A: Due to the potential for exposure to a pregnant female blood recipient, individuals taking Finalo are generally deferred from blood donation for a period of time after the last dose, according to U.S. Federal Regulations and blood donation centers.


Q: What kind of research is currently being done on Finalo?

A: While the drug is approved, various government-sponsored and registered studies (e.g., on the NIH Clinical Trials database) continue to monitor and assess its effects and long-term outcomes.


Q: Does Finalo have a risk of dependence or withdrawal symptoms?

A: Regulatory documents do not classify Finalo as having a risk of dependence. However, official post-marketing reports have noted that certain sexual side effects and psychiatric symptoms have persisted in some patients after treatment has stopped.


Q: Is Finalo safe to use if I have a chronic condition like diabetes?

A: Official contraindications do not include specific chronic conditions like diabetes. Caution is advised for those with liver function abnormalities, as the medicine is metabolized in the liver.


Q: Can Finalo cause changes in mood or sleep?

A: Post-marketing reports listed in regulatory documents include psychiatric side effects such as depression, anxiety, and suicidal ideation. Changes in sleep are not consistently highlighted in the key warnings.


Q: What is the consensus in the medical community about Finalo?

A: Regulatory bodies have approved Finasteride for its two specified uses based on clinical trial data. Official regulatory updates reflect the ongoing monitoring and assessment of reported adverse events, including psychiatric and persistent sexual side effects.


Q: Can Finalo be used in combination with physiotherapy or lifestyle changes?

A: Patient information may describe that certain non-pharmacological methods, such as managing fluid intake or reducing caffeine, may be used alongside the medication for conditions like BPH.


Q: Are there any specific organs Finalo is known to affect?

A: The medication’s action primarily affects androgen-sensitive tissues, such as the prostate and hair follicles. Adverse reactions documented in official information most commonly affect the reproductive system, including breast tissue and testicles.


Q: Is Finalo considered a high-risk medication?

A: Finalo is a prescription-only medication, and regulatory documents include warnings for serious adverse events that require caution and monitoring during use. These include the rare risks of male breast cancer and high-grade prostate cancer.


Q: Does Finalo interact with caffeine or alcohol?

A: According to official patient information, Finalo has been found to have a minimal interaction profile. No clinically meaningful interactions with food, common beverages like caffeine, or alcohol have been specifically identified.

How should Finalo be stored and disposed of?

How to Store and Dispose of Finalo (Finasteride)

Finalo tablets must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C (86 F). The product must be protected from moisture and kept in its original container with the lid tightly closed until the expiration date.

Handling and Safety

Women who are pregnant or may potentially be pregnant must not handle crushed or broken tablets due to the risk of absorption and potential harm to a male fetus. Intact tablets are film-coated. The medication must always be stored out of the sight and reach of children.

Disposal

Unused or expired Finalo must not be thrown away with household waste or disposed of in wastewater. Disposal must be conducted according to local regulatory requirements for pharmaceutical waste, often by returning the product to a pharmacist or official drug take-back location.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Finalo found in:

A-Z Index: